News

Morning Bid: Yields, stocks sag as 'Tariff Man' flexes muscles, Nvidia reports

The Asia-Pacific economic and corporate calendar is virtually empty on Thursday, allowing investors to take their cue from global drivers, two of which stand out above all others - Nvidia's earnings and U.S. President Donald Trump's latest musings on tariffs. Nvidia reported fourth-quarter earnings after the market close on Wednesday. Revenue grew 78% to $39.3 billion, beating estimates of $38.04 billion, and the firm's forecast for first-quarter revenue was also above market estimates.

Beyond Meat (NASDAQ:BYND) Exceeds Q4 Expectations

Plant-based protein company Beyond Meat (NASDAQ:BYND) announced better-than-expected revenue in Q4 CY2024, with sales up 4% year on year to $76.66 million. On the other hand, the company’s full-year revenue guidance of $327.5 million at the midpoint came in 1.3% below analysts’ estimates. Its non-GAAP loss of $0.65 per share was 44.3% below analysts’ consensus estimates.

Health Catalyst’s (NASDAQ:HCAT) Q4 Earnings Results: Revenue In Line With Expectations, Growth To Accelerate Next Year

Healthcare software provider Health Catalyst (NASDAQ:HCAT) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 6% year on year to $79.61 million. On the other hand, next quarter’s revenue guidance of $79 million was less impressive, coming in 3.5% below analysts’ estimates. Its non-GAAP profit of $0.04 per share was 47.6% below analysts’ consensus estimates.

Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings

Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 34.3% year on year to $181.9 million. On the other hand, the company’s full-year revenue guidance of $925 million at the midpoint came in 8.2% above analysts’ estimates. Its GAAP profit of $0.26 per share was 39% below analysts’ consensus estimates.

Marqeta’s (NASDAQ:MQ) Q4 Sales Beat Estimates, Stock Jumps 12.2%

Leading edge card issuer Marqeta (NASDAQ: MQ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 14.3% year on year to $135.8 million. Guidance for next quarter’s revenue was better than expected at $135.7 million at the midpoint, 1.7% above analysts’ estimates. Its GAAP loss of $0.05 per share was in line with analysts’ consensus estimates.